SCHEMBL3581923

SCHEMBL3581923

Cc1ccc(S(=O)(=O)N2CC3SC(c4ccc(OCCCCl)cc4)=NC3(O)C2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.38
TSHR P16473 2/20 0.38
MAPK1 P28482 1/20 0.38
RECQL P46063 1/20 0.38
GAA P10253 1/20 0.37
PKM P14618 1/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
APOBEC3A P31941 1/20 0.36
CTDSP1 Q9GZU7 1/20 0.36
APOBEC3G Q9HC16 1/20 0.36
ADAM17 P78536 1/20 0.36
LMNA P02545 1/20 0.36
MMP1 P03956 1/20 0.35
MMP3 P08254 1/20 0.35
MMP7 P09237 1/20 0.35
MMP9 P14780 1/20 0.35
ALDH1A1 P00352 1/20 0.35
KCNQ1 P51787 1/20 0.35
CYP3A4 P08684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3621775 0.76 PKM (0.43) TSHRGAAPKMMEN1KMT2A
SCHEMBL3577061 0.69 GPR119 (0.45)
SCHEMBL21344616 0.69 LMNA (0.41) TSHRGAAPKMMEN1KMT2A
SCHEMBL3575709 0.68 NPC1 (0.43) L3MBTL1TSHRMAPK1RECQLKMT2A
SCHEMBL4098362 0.63 DRD2 (0.55) L3MBTL1MEN1KMT2AALDH1A1CYP3A4
SCHEMBL2410855 0.62 DRD2 (0.61) L3MBTL1MEN1KMT2AALDH1A1
SCHEMBL2513630 0.59 CA12 (0.50) L3MBTL1TSHRMAPK1RECQLMEN1
SCHEMBL5825048 0.59 DRD2 (0.55) L3MBTL1MEN1KMT2A
SCHEMBL2145602 0.59 CA1 (0.46) GAAKMT2AALDH1A1CYP3A4CYP2C9
SCHEMBL504925 0.58 DPP4 (0.47) TSHRGAAPKMMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100009969-A1 Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands UCB PHARMA, S.A. (BE) 2010-01-14 US disclosed
US-20100009969-A1 Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands UCB PHARMA, S.A. (BE) 2010-01-14 US disclosed
US-20100009969-A1 Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands UCB PHARMA, S.A. (BE) 2010-01-14 US disclosed
EP-2049548-A1 FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS UCB Pharma, S.A. (BE) 2009-04-22 EP disclosed
WO-2008012010-A1 FUSED OXAZOLES & THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS UCB PHARMA, S.A. (BE) 2008-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100009969-A1 Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands HRH3, HRH4, HRH2 L3MBTL1 4680/4885TSHR 153/4885MAPK1 3144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.